PolyPid Ltd. (PYPD)
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
PolyPid Ltd.
NASDAQ:PYPDHealthcare · Biotechnology
-3.58%$5.39
AH$5.45+1.11%vs close
Mkt Cap$112.46M
Float15.52M
O/S20.86M
Vol
$ Vol
RVOL
Inst Own15.8%
SI1.4%
Earnings
Dilution
1-25 of 254 filings
…
Recent SEC filings with analysis
- 6-KPolyPid (Nasdaq: PYPD) unveiled an expanded pipeline strategy, introducing PD01B, a new Kynatrix-based product candidate delivering doxycycline directly into…
- 6-KPolyPid announced that the EMA validated its Marketing Authorization Application for D-PLEX100, its lead candidate for preventing post-abdominal surgery…
- 6-KPolyPid (Nasdaq: PYPD) announced the mutual termination of its 2022 exclusive License, Distribution and Supply Agreement with ADVANZ PHARMA for D-PLEX100 in…